What's a man to do? Treatment options for localized prostate cancer

Canadian Family Physician

Volumn 50, Issue JAN., 2004, Pages 65-72

  Pickles, Tom ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; DECISION MAKING; GENERAL PRACTITIONER; HUMAN; INTESTINE FUNCTION; MALE; PATIENT COUNSELING; PERCEPTION; PROSTATE CANCER; QUALITY OF LIFE; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SEXUAL FUNCTION; TREATMENT OUTCOME;

ADULT; AGED; BRACHYTHERAPY; DECISION MAKING; EVIDENCE-BASED MEDICINE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT CARE PLANNING; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIATION INJURIES; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 1642555817     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Davison BJ, Gleave ME, Goldenberg SL, Degner LF, Hoffart D, Berkowitz J. Assessing information and decison preferences of men with prostate cancer and their partners. Cancer Nurs 2002;25(1),42-9.
2. Lukka H, Warde P, Pickles T, Morton G, Brundage M, Souhami L. Controversies in prostate cancer radiotherapy: consensus development. Can J Urol 2001;8(4):1314-22.
3. Klotz LH, Fradet Y. Controversies in the management of localized prostate cancer: consensus development by Canadian urologists. Can J Urol 2002;9(3 Suppl 1):30-5.
4. Sobin L, Wittekind C. TNM classification of malignant tumours. 6th ed. Geneva, Switz: International Union against Cancer; 2002.
5. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman P, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347(11):781-9.
6. Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlen BJ, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347(11):790-6.
7. Akakura K, Isaka S, Akimoto S, Ito H, Okada K, Hachiya T, et al. Long-term results of a randomized trial for the treatment of stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. Urology 1999;54(2):313-8.
8. American College of Surgeons Oncology Group. A randomized trial of radical prostatectomy versus brachytherapy for patients with T1c or T2a N0 M0 prostate cancer. Durham, NC: American College of Surgeons Oncology Group; 2000. Available at: http://www.acosog.org/studies/organ_site/genitourinary/index.jsp. Accessed 2003 Dec 8.
9. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol 2001;165(5):1562-8.
10. Ross PL, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I, Sogani PC, et al. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol 2002;20(2):82-8.
11. Kattan MW, Scardino PT. Prediction of progression: nomograms of clinical utility. Clin Prostate Cancer 2002;1(2):90-6. Available at: http://www.nomograms.org. Accessed 2003 November 3.
12. Crawford ED, Bennett CL, Stone NN, Knight SJ, DeAntoni E, Sharp L, et al. Comparison of perspectives on prostate cancer: analyses of survey data. Urology 1997;50(3):366-72.
13. Litwin MS, Lubeck DP, Henning JM, Carroll PR. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol 1998;159(6):1988-92.
14. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280(11):975-80.
15. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002;167(4):1664-9.
16. McLaren DB, McKenzie M, Duncan G, Pickles T. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 1998;82(2):342-8.
17. Hu JC, Gold KF, Pashos CL, Mehta SS, Litwin MS. Temporal trends in radical prostatectomy complications from 1991 to 1998. J Urol 2003;169(4):1443-8.
18. Weldon VE, Tavel FR, Neuwirth H, Cohen R. Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J Urol 1995;153(5): 1565-9.
19. Begg CB, Riedel ER, Bach PB, Kattan MW, Schrag D, Warren JL, et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002;346(15):1138-44.
20. Hu JC, Gold KF, Pashos CL, Mehta SS, Litwin MS. Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol 2003;21(3):401-5.
21. Pickles T, Coldman A, Phillips N. The changing face of prostate cancer in British Columbia 1988-2000. Can J Urol 2002;9(3):1551-7.
22. Zelefsky MJ, Leibel SA, Kutcher GJ, Fuks Z. Three-dimensional conformal radiotherapy and dose escalation: where do we stand? Semin Radiat Oncol 1998;8(2):107-14.
23. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000;18(23):3904-11.
24. Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002;20(16):3376-85.
25. Klotz L, Gleave M, Goldenberg SL. Neoadjuvant hormone therapy: the Canadian trials. Mol Urol 2000;4(3):233-7. Discussion Mol Urol 2000;4(3):239.
26. Bolla M, Collette L, Blank L, Warde P. Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360(9327):103-6.
27. Hanks GE, Lu J, Machtay M, Venkatesen V, Pinover W, Byhardt R, et al. RTOG Protocol 92-02: a phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate [abstract]. Int J Radiat Oncol Biol Phys 2000;48(112):4.
28. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49(4):937-46.
29. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50(5):1243-52.
30. Lee WR, Hall MC, McQuellon RP, Case LD, McCullough DL. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2001;51(3):614-23.
31. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000;92(19):1582-92.
32. Talcott JA, Clark JA, Stark PC, Mitchell SP. Long-term, treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol 2001;166(2):494-9.
33. Crook J, Lukka H, Klotz L, Bestic N, Johnston M. Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer. CMAJ 2001;164(7):975-81.
34. Bucci J, Morris WJ, Keyes M, Spadinger I, Sidhu S, Moravan V. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;53(1):91-8.
35. Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001;51(1):31-40.